What is the 9-valent human papillomavirus vaccine?

The nine-valent HPV vaccine has good antigenicity. After completing the three-dose vaccination program, the positive conversion rate of serum antibodies of the relevant types can reach almost 100%. One month after the vaccination program, the maximum geometric mean antigen titer reached 100 times the antigen level after natural infection. In the next two months, the value dropped to 10 times, reaching the weight loss bottleneck period. The vaccine's antigenic level can be maintained for at least 4 years.

In clinical studies of the efficacy of the nine-valent HPV vaccine, the key observation endpoints were persistent infection with other HPV types, genital warts associated with relevant HPV types, cervical intraepithelial neoplasia (CIN), and genital or vaginal intraepithelial neoplasia (VIN or VaIN). Clinical studies have shown that vaccination with the nine-valent HPV vaccine can produce good protective effects, effectively reducing persistent infection with certain types of HPV and precancerous lesions of the cervix, vagina, and genitals, and the protective effectiveness can reach more than 90%. The nine-valent HPV vaccine includes HPV-6 and HPV-11 VLPs, which have a good preventive effect on genital warts.

Contraindications to vaccination

It is prohibited for people who have hypersensitivity to the specific ingredients or any auxiliary ingredients of the quadrivalent cervical cancer vaccine or the nine-valent HPV vaccine approved for sale in April 2018; it is prohibited for women with subacute fever, pregnant women, or those who have received the nine-valent or quadrivalent cervical cancer vaccine.

side effect

Pain, redness, swelling, fever, dizziness, headache, nausea, muscle and joint pain, fainting, etc. may occur in the vaccination area.

Interference measures

1. Before getting vaccinated, be sure to carefully understand the effectiveness, safety factor (including possible side effects) and contraindications of the vaccine.

2. After vaccination, you must stay for observation for 15 to 30 minutes and leave only after there are no other reactions.

3. Once side effects occur, cooperate closely with the vaccinators to handle the response.

Limitations

Because the cervical cancer vaccines developed and marketed do not include all high-risk types, the nine-valent HPV vaccine cannot protect all high/low-risk types from causing related tumors or diseases; therefore, the FDA approved the marketing of the nine-valent HPV vaccine and established the following nine limitations in its instructions for use:

1. This vaccine cannot cancel/stop women’s long-term cervical cancer screening (secondary prevention measure).

2. Vaccination This vaccine does not cancel/stop the highly recommended anal cancer screening.

3. This vaccine cannot protect individuals who have been infected with HPV.

4. This vaccine cannot protect against other types of related diseases other than the matching type.

5. This vaccine cannot treat diseases caused by the types of diseases described in the instructions for use.

6. This vaccine has not been confirmed to protect against private, vaginal and anal cancers caused by HPV types other than the matching type.

7. This vaccine cannot protect against diseases not caused by HPV.

8. This vaccine cannot protect all recipients.

9. The actual effectiveness of this vaccine in protecting against CIN ( ) in people over 26 years of age has not been confirmed.